KLRS - NASDAQ

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.72

-3.7%

HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$88.28M

EPS-2.8500

P/E Ratio-1.66

Earnings Date08/12/2026

klrs

Free Cash Flow

Last Annual Value

-43.18M

3-Year CAGR

-64%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Kalaris Therapeutics Inc Competitors Analysis of Free Cash Flow

KLRS · NASDAQ

Company	Free Cash Flow	CAGR 3Y	CAGR 5Y	CAGR 10Y
Kalaris Therapeutics Inc NASDAQ:KLRS	-43.18M	N/A	N/A	N/A
Ovid Therapeutics Inc. NASDAQ:OVID	-38.33M	N/A	N/A	N/A
Artiva Biotherapeutics, Inc. NASDAQ:ARTV	-79.34M	N/A	N/A	N/A
Shattuck Labs, Inc. NASDAQ:STTK	-39.95M	N/A	N/A	N/A
Context Therapeutics Inc. NASDAQ:CNTX	-26.42M	N/A	N/A	N/A
Metagenomi, Inc. Common Stock NASDAQ:MGX	-89.47M	N/A	N/A	N/A
Adverum Biotechnologies, Inc. NASDAQ:ADVM	-92.85M	N/A	N/A	N/A
ALX Oncology Holdings Inc. NASDAQ:ALXO	-84.35M	N/A	N/A	N/A
Fractyl Health, Inc. Common Stock NASDAQ:GUTS	-90.89M	N/A	N/A	N/A
Spruce Biosciences, Inc. NASDAQ:SPRB	-33.33M	N/A	N/A	N/A
Oramed Pharmaceuticals Inc. NASDAQ:ORMP	-11.08M	N/A	N/A	N/A

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.72, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

HIDDEN

Intrinsic Value

Current Price: $4.72

Related Guides

Blog Categories

Continue your KLRS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.